
Heart Failure 2026 Data Highlight Vutrisiran’s Strong Benefits Across ATTR-CM Patient Groups
New Heart Failure 2026 Analyses Highlight Consistent Clinical Benefits of Vutrisiran Across Diverse ATTR-CM Patient Groups Alnylam Pharmaceuticals has announced new analyses from its Phase 3 HELIOS-B clinical trial evaluating vutrisiran in patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM), providing…












